HK1019555A1 - Effervescent bisphosphonate formulation - Google Patents

Effervescent bisphosphonate formulation

Info

Publication number
HK1019555A1
HK1019555A1 HK99104703A HK99104703A HK1019555A1 HK 1019555 A1 HK1019555 A1 HK 1019555A1 HK 99104703 A HK99104703 A HK 99104703A HK 99104703 A HK99104703 A HK 99104703A HK 1019555 A1 HK1019555 A1 HK 1019555A1
Authority
HK
Hong Kong
Prior art keywords
bisphosphonate formulation
effervescent
effervescent bisphosphonate
formulation
source
Prior art date
Application number
HK99104703A
Other languages
English (en)
Inventor
Ashok V Katdare
Kenneth A Kramer
Colin R Gardner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9613183.4A external-priority patent/GB9613183D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HK1019555A1 publication Critical patent/HK1019555A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
HK99104703A 1996-05-17 1999-10-22 Effervescent bisphosphonate formulation HK1019555A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1788196P 1996-05-17 1996-05-17
GBGB9613183.4A GB9613183D0 (en) 1996-06-24 1996-06-24 Effervescent alendronate formulation
PCT/US1997/008055 WO1997044017A1 (en) 1996-05-17 1997-05-13 Effervescent bisphosphonate formulation

Publications (1)

Publication Number Publication Date
HK1019555A1 true HK1019555A1 (en) 2000-02-18

Family

ID=26309559

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99104703A HK1019555A1 (en) 1996-05-17 1999-10-22 Effervescent bisphosphonate formulation

Country Status (9)

Country Link
EP (1) EP0939624B1 (xx)
JP (2) JP2000511178A (xx)
AT (1) ATE256456T1 (xx)
AU (1) AU712710B2 (xx)
CA (1) CA2254060C (xx)
DE (1) DE69726879T2 (xx)
ES (1) ES2210529T3 (xx)
HK (1) HK1019555A1 (xx)
WO (1) WO1997044017A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID24096A (id) * 1997-07-22 2000-07-06 Merck & Co Inc Metode untuk menghambat resorpsi tulang
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
IL121623A (en) * 1997-08-26 2000-06-29 Unipharm Ltd Process for the preparation of solid oral dosage forms comprising alendronic acid
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
EP1228761A3 (en) * 2001-02-01 2003-01-15 Riderway Corporation Liquid pharmaceutical composition for treating bone diseases
DK1490024T3 (da) * 2002-03-06 2012-04-10 Effrx Pharmaceuticals Sa Alendronatholdige brusesammensætninger
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
GR1004660B (el) * 2003-06-25 2004-08-25 ������������, �������� ��� ����������� �������� �������� ��� �.�. ��������-������������ �.�. Βελτιωμενες φαρμακευτικες συνθεσεις του τριυδρικου αλενδρονικου νατριου και μεθοδοι παρασκευης τους
EP1708686B1 (en) 2003-12-31 2011-02-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
AU2004311879B2 (en) 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
ES2349584T3 (es) * 2004-05-24 2011-01-05 Warner Chilcott Company, Llc Forma de dosificación sólida entérica para administración oral de un bifosfonato que contiene un agente quelante.
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
WO2006100527A1 (en) * 2005-03-24 2006-09-28 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Effervescent tablet containing sodium alendronate and related use and process
DE102006054260A1 (de) * 2006-02-28 2007-09-27 Lohmann Animal Health Gmbh & Co. Kg Wasser stabilisierende Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP2055297A1 (en) * 2007-11-05 2009-05-06 Merz Pharma GmbH & Co. KGaA Therapy option for recoloration of hair via bisphosphonates by physiological repigmentation with age-related and/or premature "grayed" patients
WO2009137078A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
KR101118794B1 (ko) 2009-11-10 2012-06-13 동아제약주식회사 비스포스포네이트를 함유하는 약학 조성물
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
TR201100151A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut İbandronate formülasyonu.
EP2983719A4 (en) * 2013-03-15 2017-01-25 Mylan Inc. Manufacturing process for effervescent dosage forms
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1195993B (it) * 1984-01-12 1988-11-03 Gentili Ist Spa Forme farmaceutiche a base di difosfonati
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
ES2074769T3 (es) * 1991-07-01 1995-09-16 Gergely Gerhard Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions

Also Published As

Publication number Publication date
EP0939624B1 (en) 2003-12-17
JP2000511178A (ja) 2000-08-29
EP0939624A1 (en) 1999-09-08
ATE256456T1 (de) 2004-01-15
AU3005397A (en) 1997-12-09
ES2210529T3 (es) 2004-07-01
AU712710B2 (en) 1999-11-11
WO1997044017A1 (en) 1997-11-27
JP2009167200A (ja) 2009-07-30
CA2254060C (en) 2007-05-01
CA2254060A1 (en) 1997-11-27
DE69726879T2 (de) 2004-10-14
DE69726879D1 (de) 2004-01-29

Similar Documents

Publication Publication Date Title
HK1019555A1 (en) Effervescent bisphosphonate formulation
ZA974207B (en) Effervescent bisphosphonate formulation.
ZA971358B (en) Liquid oral compositions comprising a calcium compound and an acidulant.
GB9811059D0 (en) Polyamino acid vesicles
EP1011475A4 (en) SYSTEM FOR INSERTING A SEWING ANCHOR
EP1032313A4 (en) SUTURE ANCHOR INSERTION SYSTEM
ZA977086B (en) NAALADase inhibitors.
EP0857718A4 (en) ENDOTHELIN ANTAGONIST
ZA988967B (en) Lactam metalloprotease inhibitors.
AU4277797A (en) Strap tie connector
DE69719775D1 (en) Thrombin inhibitoren
AU1857600A (en) Ion channel modulating agents
ZA9711728B (en) A face mask.
ZA989143B (en) Method of preparing a dairy spread.
GB2316945B (en) Preparation of 3-amino-1-hydroxypropane-1,1-diphosphonic acid
AU5766499A (en) Method for generating video programs, variants, and system for realising this method
AU4806497A (en) Glyoxylic compound comprising one or more active ingredient
DK0969849T3 (da) Stabilt, fast præparat indeholdende vitamin D3 og tricalciumphosphat
EP1820497A3 (en) Effervescent bisphosphonate formulation
AUPP639898A0 (en) An improved anchor connection
AU7687698A (en) Face mask
AU3998497A (en) A combination preparation containing tramadol and a calcium channel antagonist
EP1018336A4 (en) carcinostatic
GB9828395D0 (en) Self engaging type tape
AU7897798A (en) Circuit for transmitting messages

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20170512